Program Overview
This CME program was derived from content presented at the Clinical Congress of Rheumatology 2018 annual meeting in Destin, Florida. The expert faculty, Dr. Grace C. Wright, will discuss the state of disease of rheumatoid arthritis (RA) in an ever evolving treatment landscape. Recent clinical trial data for approved biologic therapies will be analyzed along with data for emerging JAK1/JAK2 inhibitor therapeutics. The role of assessing and managing cardiovascular risk to reduce comorbidities will be outlined. The faculty will relay optimal methods for individualizing treatment plans to reduce disease activity and pain levels in RA. Upon completion of this educational activity, learners will have a better understanding of how to utilize recent trial data and therapeutic guidelines in practice to improve patient outcomes and quality of life.
Target Audience
Rheumatologists and other health care providers that are involved in the management of rheumatoid arthritis
Learning Objectives
1. Review the state of the science of rheumatoid arthritis in 2018
2. Examine clinical trial data for emerging therapeutics, including biologics and JAK inhibitors
3. Analyze biosimilars and their impact in rheumatology
4. Assess the role of TNF cycling versus switching to a different mechanism of action (MOA)
5. Evaluate the impact of cardiovascular risk in RA
Faculty
Grace C. Wright, MD, PhD
Clinical Associate Professor of Medicine
New York University School of Medicine
President, Association of Women in Rheumatology
New York City, New York
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
| Faculty | Relationship Identified With: |
| Grace C. Wright, MD, PhD | Consultant/Advisor: AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Crescendo Bioscience, Inc.; Genentech Inc.; Janssen Pharmaceuticals, Inc.; Lilly USA, LLC; Mallinckrodt Pharmaceuticals; Medac Pharma, Inc.; Pfizer, Inc.; UCB, Inc.Speaker’s Bureau: AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Crescendo Bioscience, Inc.; Genentech Inc.; Lilly USA, LLC; Mallinckrodt Pharmaceuticals; Novartis AG; UCB, Inc. |
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity is supported by educational grants from Lilly USA, LLC and Sanofi, Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Lilly USA, LLC and Sanofi, Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact [email protected].
